Should I buy or sell Equillium stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EQ shares. View EQ analyst ratings or view top-rated stocks .

What is Equillium's stock price target for 2024?

2 analysts have issued 1-year target prices for Equillium's stock. Their EQ share price targets range from $2.80 to $5.00. On average, they predict the company's share price to reach $3.90 in the next year. This suggests a possible upside of 125.4% from the stock's current price. View analysts price targets for EQ or view top-rated stocks among Wall Street analysts .

How have EQ shares performed in 2024?

Equillium's stock was trading at $0.7230 at the start of the year. Since then, EQ stock has increased by 139.3% and is now trading at $1.73. View the best growth stocks for 2024 here .

When is Equillium's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EQ earnings forecast .

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) announced its earnings results on Monday, March, 25th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.10. The business had revenue of $9.21 million for the quarter, compared to analysts' expectations of $8.85 million. Equillium had a negative net margin of 36.96% and a negative trailing twelve-month return on equity of 51.82%.

What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?

10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com . Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EQ

Equillium (EQ) Stock Price, News & Analysis

→ Nvidia Has a BIG Problem — Here’s Who Benefits MOST (From Weiss Ratings) (Ad)

Free EQ Stock Alerts

$1.73

-0.06 (-3.35%)

(As of 03:00 PM ET)

Compare

Today's Range: $1.71
▼
$1.84
50-Day Range: $1.52
▼
$3.00
52-Week Range: $0.45
▼
$3.25

Volume: 66,590 shs
Average Volume: 329,530 shs
Market Capitalization: $61.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.90

Get Equillium alerts:

Equillium MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 125.4% Upside
$3.90 Price Target
Short Interest: Healthy
6.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.08) to ($0.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.03 out of 5 stars

Medical Sector

792nd out of 914 stocks

Pharmaceutical Preparations Industry

356th out of 413 stocks

3.5

Analyst's Opinion

Consensus Rating
Equillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Equillium has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.27% of the float of Equillium has been sold short.
Short Interest Ratio / Days to Cover
Equillium has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Equillium has recently decreased by 3.52%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Equillium does not currently pay a dividend.
Dividend Growth
Equillium does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EQ.

0.0

News and Social Media Coverage

Search Interest
Only 8 people have searched for EQ on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Equillium to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Equillium insiders have not sold or bought any company stock.
Percentage Held by Insiders
30.00% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.05% of the stock of Equillium is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Equillium are expected to decrease in the coming year, from ($0.08) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Equillium is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Equillium is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Equillium has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

This Little-Known Stock Controls the Future of AI

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

About Equillium Stock (NASDAQ:EQ)

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

EQ Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EQ Stock News Headlines

April 3, 2024 | businesswire.com

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 2, 2024 | msn.com

Biotech Rallies Strongly On Second Consecutive Positive Headline

April 1, 2024 | finance.yahoo.com

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

March 27, 2024 | marketwatch.com

Equillium Shares Fall After Swing to 4Q Loss

March 25, 2024 | investorplace.com

EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023

March 25, 2024 | benzinga.com

Equillium: Q4 Earnings Insights

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2024 | businesswire.com

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

March 22, 2024 | businesswire.com

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

March 12, 2024 | msn.com

BioXcel Therapeutics GAAP EPS of -$0.76 beats by $0.15, revenue of $0.38M misses by $0.36M

March 3, 2024 | finance.yahoo.com

ROOT Sep 2024 7.500 put

February 24, 2024 | finance.yahoo.com

SMCI Mar 2024 970.000 call

February 24, 2024 | finance.yahoo.com

SMCI Mar 2024 765.000 call

February 24, 2024 | sg.finance.yahoo.com

SMCI Mar 2024 800.000 put

February 23, 2024 | uk.finance.yahoo.com

SMCI Feb 2024 1460.000 put

February 23, 2024 | finance.yahoo.com

SMCI Mar 2024 695.000 put

February 23, 2024 | benzinga.com

Equillium Stock (NASDAQ:EQ), Short Interest Report

February 13, 2024 | finance.yahoo.com

November 20, 2023 | finance.yahoo.com

EQ Bank Card launches in Québec as Carte Banque EQ

November 15, 2023 | benzinga.com

Equillium Stock (NASDAQ:EQ), Analyst Ratings, Price Targets, Predictions

November 13, 2023 | finance.yahoo.com

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

November 8, 2023 | finance.yahoo.com

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

November 6, 2023 | finance.yahoo.com

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

November 2, 2023 | finance.yahoo.com

Equillium, Inc. (EQ) Stock Historical Prices & Data - Yahoo Finance

November 1, 2023 | msn.com

Equillium (EQ) Price Target Increased by 11.23% to 7.24

See More Headlines

Receive EQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EQ
CUSIP: N/A
CIK: 1746466
Web: equilliumbio.com
Phone: (858) 240-1200
Fax: N/A
Employees: 44
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.90
High Stock Price Target: $5.00
Low Stock Price Target: $2.80
Potential Upside/Downside: +117.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,340,000.00
Net Margins: -36.96%
Pretax Margin: -35.35%
Return on Equity: -51.82%
Return on Assets: -22.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.79
Quick Ratio: 1.79

Sales & Book Value

Annual Sales: $36.08 million
Price / Sales: 1.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.64 per share
Price / Book: 2.80

Miscellaneous

Outstanding Shares: 35,260,000
Free Float: 24,679,000
Market Cap: $63.12 million
Optionable: Not Optionable
Beta: 1.62

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Daniel Mark Bradbury (Age 63)
Executive Chairman
Comp: $158k
Mr. Bruce D. Steel C.F.A. (Age 58)
Co-Founder, President, CEO & Director
Comp: $796.95k
Ms. Christine Zedelmayer M.B.A. (Age 54)
P.M.P., Senior VP & COO
Comp: $561.75k
Dr. Stephen Connelly Ph.D. (Age 42)
Chief Scientific Officer & Director
Comp: $579.6k
Mr. Jason A. Keyes (Age 53)
Chief Financial Officer
Mr. Michael Moore
Vice President of Investor Relations & Corporate Communications
Dr. Matthew Ritter Ph.D.
Senior Vice President of Corporate Development
Mr. Joel M. Rothman (Age 55)
Chief Development Officer
Dr. Maple Fung M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

EQ Stock Analysis - Frequently Asked Questions

Should I buy or sell Equillium stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EQ shares.
View EQ analyst ratings or view top-rated stocks.
What is Equillium's stock price target for 2024?: 2 analysts have issued 1-year target prices for Equillium's stock. Their EQ share price targets range from $2.80 to $5.00. On average, they predict the company's share price to reach $3.90 in the next year. This suggests a possible upside of 125.4% from the stock's current price.
View analysts price targets for EQ or view top-rated stocks among Wall Street analysts.
How have EQ shares performed in 2024?: Equillium's stock was trading at $0.7230 at the start of the year. Since then, EQ stock has increased by 139.3% and is now trading at $1.73.
View the best growth stocks for 2024 here.
When is Equillium's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EQ earnings forecast.

How were Equillium's earnings last quarter?: Equillium, Inc. (NASDAQ:EQ) announced its earnings results on Monday, March, 25th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.10. The business had revenue of $9.21 million for the quarter, compared to analysts' expectations of $8.85 million. Equillium had a negative net margin of 36.96% and a negative trailing twelve-month return on equity of 51.82%.
What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?: 10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend.
When did Equillium IPO?: Equillium (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.
How do I buy shares of Equillium?: Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EQ) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial